ALN1003 shows strong potential in obesity treatment studies
Alaunos Therapeutics reported promising early data on ALN1003, demonstrating significant weight loss and liver health improvements in mouse models. The company is focused on further preclinical studies and refining its drug formulation, positioning ALN1003 as a potential non-hormonal treatment alternative as it seeks additional funding to sustain operations through mid-2026.
View signal analysis